Introduction: Amoxicillin and clavulanic combination possess bactericidal effect against many bacterial species. Amoksiklav QUICKTAB , combining these two substances in oral dispersible tablets, is a new form. The aim of the study was to analyse this confection safety profile and tolerance in Polish population outpatient setting. Material and method: The retrospective observational study governed data from Amoksiklav QUICKTAB adult patients treatment realized in outpatient setting. The demographic and anamnestic data ecommended control visit, self-estimated treatment tolerance and patient’s compliance. Data obtained were statistically analysed with Statistica 9.0 PL software. Results: In 76% of cases Amoksiklav QUICKTAB was recommended in upper respiratory tract infections, over 8% of total cases it was the second antibacterial cure. The most often regimen was 2×1000 mg per 7 days. A control visit was recommended in over 70% of patients, more often in the elder ones. Then 90% of patients reported drug usage straight to recommendation. Most of patients tolerated this formulation very well or well. Adverse effects were registered in less than 2% of cured patients with mild intensity in a half of them, there were no side effects another from previously described. Conclusions: Amoksiklav QUICKTAB in dose of 650 mg and 1000 mg is a safe formulation. It does not cause any other side effects than previously recorded for such combination of active substances. The treatment is mostly well tolerated, the tolerance is connected with the age of patient and concomitant diseases. Oral dispersible tablet is more preferable by the older patients.